Lv2
118 积分 2025-03-25 加入
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
18天前
已完结
Development of Globo-H conjugated bacteriophage Qβ mutant virus-like particles as an anticancer vaccine
18天前
已完结
Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions
27天前
已完结
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity
1个月前
已完结
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors
1个月前
已完结
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
1个月前
已完结
Artificial intelligence in drug development
2个月前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
3个月前
已完结
Cell cycle control in cancer
3个月前
已完结
The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond
3个月前
已完结
皖公网安备34019202002308
